Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and Survival Rates of Frontotemporal Lobar Degeneration: Population-Based Registry Study.

Neurology·2026
Same author

PhysioMio: bilateral and longitudinal HD-sEMG dataset of 16 hand gestures from 48 stroke patients.

Scientific data·2026
Same author

Guiding Multiple Sclerosis Care: An Update to the 2013 Consensus Statement from the MS in the 21st Century Steering Group.

Neurology and therapy·2025
Same author

The association of upper limb sensorimotor capacity, everyday inpatient behavior, and the effects of neurorehabilitation in persons with multiple sclerosis and stroke: a mixed-design study.

Journal of neuroengineering and rehabilitation·2025
Same author

Outside the Laboratory Assessment of Upper Limb Laterality in Patients With Stroke: A Cross-Sectional Study.

Stroke·2023
Same author

Can Growth Hormone Lead to a Faster Recovery from Guillain-Barré Syndrome? Case Report of the First Therapeutic Use in One Patient.

Case reports in neurology·2023

Related Experiment Video

Updated: Jul 6, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Treating multiple sclerosis with monoclonal antibodies.

Mathias Buttmann1, Peter Rieckmann

  • 1Julius-Maximilians University, Department of Neurology, Josef-Schneider-Str. 11, 97080 Würzburg, Germany. m.buttmann@uni-wuerzburg.de

Expert Review of Neurotherapeutics
|March 19, 2008
PubMed
Summary

This review explores four therapeutic monoclonal antibodies (mAbs) for multiple sclerosis (MS) treatment. It details their development, mechanisms, clinical trials, and future market potential in MS therapy.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Related Experiment Videos

Last Updated: Jul 6, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Therapeutic monoclonal antibodies (mAbs) represent a significant advancement in targeted therapies for multiple sclerosis (MS).
  • Several mAbs, including natalizumab, alemtuzumab, rituximab, and daclizumab, have shown promise in clinical trials for managing MS.
  • Understanding the development, nomenclature, and target antigens of these mAbs is crucial for their effective application in MS treatment.

Purpose of the Study:

  • To provide a comprehensive overview of four key therapeutic monoclonal antibodies (mAbs) for multiple sclerosis (MS).
  • To critically analyze the scientific rationale, modes of action, and clinical trial data for these mAbs in MS therapy.
  • To forecast the potential market evolution of these mAbs as future therapeutics for MS.

Main Methods:

  • Review of existing literature on therapeutic monoclonal antibodies (mAbs) for multiple sclerosis (MS).
  • Analysis of non-MS indications, target antigen expression and function, and scientific rationales for MS therapy.
  • Critical discussion of clinical trial data, including protocols, interim analyses, safety considerations, and diagnostic approaches for natalizumab.

Main Results:

  • Four therapeutic monoclonal antibodies (mAbs) – natalizumab, alemtuzumab, rituximab, and daclizumab – are discussed in detail regarding their application in multiple sclerosis (MS).
  • The review covers their development, target antigens, mechanisms of action, pharmacological properties, and clinical trial outcomes.
  • Specific attention is given to natalizumab's safety profile and the use of neutralizing antibodies.

Conclusions:

  • Therapeutic monoclonal antibodies (mAbs) offer potent, targeted approaches to modify the course of multiple sclerosis (MS).
  • The discussed mAbs (alemtuzumab, daclizumab, natalizumab, rituximab) have demonstrated efficacy in clinical trials, with natalizumab already approved.
  • Further evaluation of ongoing trials and safety data will shape the future market integration of these advanced MS therapeutics.